Pharmaceuticals News and Research

RSS

Shire, Janssen enter development and marketing agreement for Resolor

Shire plc, the global specialty biopharmaceutical company, announced today that it has acquired the rights to develop and market Resolor (prucalopride) in the United States (US) in an agreement with Janssen Pharmaceutica N.V.

11 Jan 2012

UCLA researchers identify chemical changes in brains of patients with early-onset Alzheimer's

With a lack of effective treatments for Alzheimer's, most of us would think long and hard about whether we wanted to know years in advance if we were genetically predisposed to develop the disease. For researchers, however, such knowledge is a window into Alzheimer's disease's evolution.

11 Jan 2012

Warwick researchers and Canadian scientists partner in new project on antibiotic resistance

University of Warwick researchers have teamed up with Canadian scientists on a -2.2 million project to search for new antibiotics which will beat resistance in deadly "superbugs".

11 Jan 2012

New UC San Diego-Roche Extending Innovation Network program launched

The new UC San Diego-Roche Extending Innovation Network (EIN) program has been launched with selection of its first three research projects at the University of California, San Diego School of Medicine.

11 Jan 2012

Starpharma receives FDA Special Protocol Assessment for bacterial vaginosis phase 3

Starpharma today announced that it has received final written agreement from the FDA on the design of its Phase 3 clinical studies of VivaGel® for the treatment of bacterial vaginosis (BV) under the FDA’s Special Protocol Assessment (SPA) scheme.

10 Jan 2012

Statins may raise type 2 diabetes risk

A new study suggests statin medications used to lower cholesterol may raise the risk of diabetes to a slight extent. Study authors advise patients not to stop taking their medications without talking to a doctor, because statins' proven power to prevent heart attacks and strokes outweighs any potential increase in type 2 diabetes risk.

10 Jan 2012

Shire acquires rights to develop and market Resolor in the U.S.

10 Jan 2012

END7 campaign aims to combat seven major NTDs by 2020

Launched today, the END7 campaign is dedicated to eliminating seven major neglected tropical diseases (NTDs) as a public health threat to poor communities by the end of 2020.

10 Jan 2012

Telormedix raises 7.5 million CHF

Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, today announced that it has raised 7.5 Million CHF from existing investors Aravis Venture and Proquest Investments.

10 Jan 2012

QIAGEN's therascreen EGFR Mutation Detection Kit receives Japanese regulatory approval

QIAGEN today announced the regulatory approval of its therascreen EGFR Mutation Detection Kit RGQ in Japan. EGFR, the epidermal growth factor receptor, has been shown to play an important role in certain cancers and is the target of many new anticancer drugs.

From QIAGEN Manchester Limited 10 Jan 2012

Roundup: Iowa weighs mental health care changes; Ariz. clinic seeks to cut ER costs

Republican and Democratic legislators and Gov. Terry Branstad have said they want to reform Iowa's mental health system to reduce waiting lists and provide more equitable services. Currently, each of Iowa's counties performs or contracts for mental health services for indigent residents. Critics contend the 99-county system has led to pockets of inferior, inequitable service, particularly in rural areas.

10 Jan 2012

Amylin outlines key strategic priorities for 2012

Amylin Pharmaceuticals, Inc. today outlined its key strategic priorities for 2012, with a strong focus on driving the global commercial value of its diabetes franchise.

10 Jan 2012

Mylan confirms Actoplus Met XR patent challenge

Mylan Inc. today confirmed that the company has been sued by Takeda Pharmaceutical Company, Watson Pharmaceuticals and Andrx Labs in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Pioglitazone Hydrochloride and Extended-release Metformin Hydrochloride tablets, 15 mg/1000 mg and 30 mg/1000 mg.

9 Jan 2012

Positive interim data from Idenix IDX184 12-week phase IIb trial on HCV

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced interim data from a 12-week phase IIb clinical trial of IDX184, the Company's lead product candidate for the treatment of hepatitis C virus (HCV) infection.

9 Jan 2012

Novartis recalls four OTC drugs citing factory malfunction

Swiss pharmaceutical firm Novartis has announced that it is recalling four different products sold over the counter in the United States after receiving reports that there if malfunction at one of its plants.

9 Jan 2012

Idenix Pharmaceuticals makes progress with its HCV development pipeline

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the advancement of its hepatitis C virus development pipeline.

9 Jan 2012

Merck selects Idera Pharmaceuticals' TLR agonists for evaluation, use as vaccine adjuvant candidates

Idera Pharmaceuticals, Inc. today announced that Merck, known as MSD outside the United States and Canada, has selected several novel Toll-like Receptor agonists targeted to TLR7, TLR8 or TLR9 for evaluation and use as vaccine adjuvant candidates under the companies' collaboration and license agreement.

9 Jan 2012

Pacira provides updated timing for commercial launch of EXPAREL

Pacira Pharmaceuticals, Inc. today provided updated timing for its commercial launch of EXPAREL (bupivacaine liposome injectable suspension), a non-opioid analgesic that was approved by the U.S. Food and Drug Administration (FDA) for administration into the surgical site to produce postsurgical analgesia.

9 Jan 2012

Presidio completes PPI-668 Phase 1a study on hepatitis C

Presidio Pharmaceuticals, Inc. announced today the successful completion of a Phase 1a dose-ranging assessment of PPI-668, a potent, pan-genotypic second-generation hepatitis C virus (HCV) NS5A inhibitor, in healthy volunteers and subsequent advancement to a Phase 1b assessment of the dose-related efficacy in hepatitis C patients.

9 Jan 2012

Genentech, Xenon partner to discover and develop novel pain relieving medicines

Xenon today announced a strategic alliance with Genentech, a member of the Roche Group, to discover and develop compounds and companion diagnostics for the potential treatment of pain.

9 Jan 2012